Athero Review - Issue 2/2017
clinical studies
87
93
Comments on the Glagov study
Tomáš Kovárník, Jan Pudil, Kristýna Bayerová
107
The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition
Michal Vrablík, Eva Tůmová
reviews
114
Can we improve primary prevention of ischaemic heart disease? Which way?
Ján Murín, Miroslav Pernický, Martin Wawruch
118
122
125
130
Changes in the lipid spectrum in endocrinopathies
Patrícia Páleníková, Juraj Payer
136
Athero Review
2017 Issue 2
Most read in this issue
- What is the role of nutriceuticals in dyslipidemia management? Armolipid Plus
- Combination treatment with antihypertensive and hypolipidemic drugs
-
Remnant cholesterol: a fact or fiction?
Reflection on the problems related to remnant cholesterol - Changes in the lipid spectrum in endocrinopathies